All Drug Discovery articles – Page 18
-
NewsDNA repair secrets of naked mole-rats may guide new drug discovery
New research has demonstrated how tiny tweaks in a DNA-sensing enzyme may hold the key to the naked mole-rat’s extraordinary lifespan – offering insights that could one day inform therapies for aging and age-related diseases.
-
NewsHIV antibody 04_A06 almost neutralises all strains
A newly discovered antibody, 04_A06, has shown unprecedented effectiveness against HIV, neutralising 98.5 percent of tested strains and permanently suppressing the virus in humanised mice.
-
NewsNew UCLA drug could restore heart and organ function
UCLA researchers have developed a monoclonal antibody, AD-NP1, that blocks ENPP1 to enhance heart repair and reduce scar tissue.
-
NewsNew nanotherapy clears amyloid-β reversing Alzheimer’s in mice
Researchers have developed bioactive nanoparticles that restore the brain’s blood-brain barrier and clear toxic proteins, reversing Alzheimer’s symptoms in mice and offering a promising new approach to treating the disease.
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
-
NewsBlocking SLAMF6 enables T cells to kill leukaemia cells
Researchers have discovered a surface protein that helps acute myeloid leukaemia cells evade the immune system, offering potential insights to aid the development of new treatments.
-
NewsKidney organoids show APOL1 gene’s role in chronic kidney disease
New research using stem cell-derived kidney organoids reveals how APOL1 gene mutations disrupt mitochondrial function in kidney cells – potentially leading to new targeted treatments.
-
ArticleBeyond templates: advancing protein–protein interaction structure prediction with AI
Dr Alan Nafiiev evaluates template-based, docking and template-free approaches to PPI prediction, highlighting how AI can enhance structural accuracy.
-
ArticleFighting MS progression: why GPR17 is the target to watch
Despite major advances in multiple sclerosis treatment, stopping disease progression has remained out of reach. Targeting the receptor GPR17 may harness the brain’s own repair system, offering the prospect of genuine remyelination and lasting benefit for patients.
-
NewsHypoxia and EUDAL: the hidden drivers of oral cancer survival
A newly discovered RNA molecule, EUDAL, helps oral cancers survive chemotherapy by keeping a key growth protein permanently active. Researchers say targeting EUDAL could predict resistance and improve treatment outcomes.
-
NewsSenolytic drug combo boosts cancer immunotherapy and reduces side effects
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
-
ArticleMass spectrometry workflows powering the future of biologics
Analysing complex biologics is one of drug discovery’s biggest challenges. At Genentech, Rachel Shi is developing MS workflows that deliver clearer answers, faster.
-
ArticleAccessible automation may change your day-to-day sooner than you think
Automation is fast and precise, but too often expensive and hard to use. Now modular, DIY tools are breaking down barriers and putting lab automation in every researcher’s hands.
-
NewsTiny models, powerful insights: how organoids are driving precision oncology
A new review has highlighted how three-dimensional organoid models are transforming cancer research by replicating the complexity of human tumours – bringing precision oncology closer to the clinic.
-
ArticleFrom data to therapy: emerging tech driving cancer drug discovery
Multiomics, AI and liquid biopsies are giving researchers real-time insight into tumour biology and enabling more personalised cancer therapies. Find out how these technologies are advancing biomarker discovery, improving patient stratification, and guiding the design of new treatments.
-
NewsProtecting bones from cancer damage: targeting the UPR pathway
New research highlights how cancer hijacks the unfolded protein response (UPR) in bone cells – potentially allowing for the development of therapies that target this pathway to prevent fractures.
-
NewsGlioblastoma treatment boosted by new drug combination strategy
Researchers in China have discovered how glioblastoma adapts to low-oxygen conditions – revealing a new treatment strategy that combines an orphan drug with standard chemotherapy to overcome resistance.
-
ArticleInside Zasocitinib: a new model for TYK2 inhibition in immune-mediated diseases
Zasocitinib is a highly selective, investigational TYK2 inhibitor developed to target immune-mediated diseases with fewer off-target effects than traditional JAK inhibitors. This article explores its mechanism, selectivity data and clinical progress.
-
NewsThe road to safer painkillers: the role of the EP2 receptor
NYU researchers have identified a receptor in prostaglandins that triggers pain without affecting inflammation – which could lead to safer, more targeted pain treatments.
-
NewsMarine sponges could hold the key to new Leishmaniasis treatments
Japanese researchers have discovered potent new compounds from marine sponges that could transform the treatment of leishmaniasis – a neglected tropical disease affecting millions worldwide.